Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Budesonide Oral Suspension Continuation Study in EoE
NCT03245840Phase 3Terminated
- Sponsor
- Takeda
- Start
- Oct 2017
- Primary completion
- Apr 2022
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of EPI-EE in eosinophilic esophagitis (EoE), sponsored by Takeda. Started Oct 2017; status: terminated.
02
Drugs
EPI-EE
03
Conditions
eosinophilic esophagitis (EoE)
Beyond the preview
Go deeper on NCT03245840.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03245840.